Chemistry:JBI-589
From HandWiki
JBI-589 is an experimental drug which acts as an orally active, selective inhibitor of the enzyme peptidylarginine deiminase 4 (PAD4). It has antiinflammatory effects and has been researched for potential use in the treatment of arthritis and some forms of cancer.[1][2][3][4]
See also
- AFM-30a
- BB-Cl-Amidine
- GSK484
References
- ↑ "A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression". Cancer Research 82 (19): 3561–3572. October 2022. doi:10.1158/0008-5472.CAN-21-4045. PMID 36069973.
- ↑ "Alleviation of arthritis through prevention of neutrophil extracellular traps by an orally available inhibitor of protein arginine deiminase 4". Scientific Reports 13 (1). February 2023. doi:10.1038/s41598-023-30246-2. PMID 36823444. Bibcode: 2023NatSR..13.3189G.
- ↑ "Inhibition of protein arginine deiminase 4 prevents inflammation-mediated heart failure in arthritis". Life Science Alliance 6 (10). October 2023. doi:10.26508/lsa.202302055. PMID 37500179.
- ↑ "Peptidylarginine deiminase (PAD): A promising target for chronic diseases treatment". International Journal of Biological Macromolecules 278 (Pt 3). October 2024. doi:10.1016/j.ijbiomac.2024.134576. PMID 39127273.
 |  |
